Bibliography
- Buhimschi CS, Weiner CP. Medications in pregnancy and lactation: part 1. Teratology. Obstet Gynecol 2009;113:166-88
- Speirs AL. Thalidomide and congenital abnormalities. Lancet 1962;1:303-5
- Kim JH, Scialli AR. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 2011;122:1-6
- European Medicines Agency and Heads of Medicine Agencies. Guideline on good pharmacovigilance practices. Module V - Risk management systems. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf [Last accessed 12 December 2012]
- Breitkreutz I, Anderson KC. Thalidomide in multiple myeloma–clinical trials and aspects of drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 2008;4:973-85
- Abroms L, Maibach E, Lyon-Daniel K, Feldman SR. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 2006;3:e483
- European Medicines Agency. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landing_page.jsp [Last accessed 15 December 2013]
- Heads of Medicines Agencies. Available from: http://mri.medagencies.org/Human/ [Last accessed 15 December 2013]
- Coloma PM, Schuemie MJ, Trifiro G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 2011;20:1-11
- InterAction database. Available from: www.IADB.nl [Last accessed 17 June 2012]
- Pieper PG, Hoendermis ES. Pregnancy in women with pulmonary hypertension. Neth Heart J 2011;19:504-8
- European Medicines Agency (EMA). European Public Assessment Report of Revatio. Scientific discussion. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000638/WC500055837.pdf [Last accessed 12 April 2013]
- European Medicines Agency (EMA). European Public Assessment Report. Adcirca. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001021/WC500069602.pdf [Last accessed 23 June 2013]
- Summary of Product Characteristics. Methotrexate. Available from: http://db.cbg-meb.nl/IB-teksten/h101493.pdf [Last accessed 23 June 2013]
- European Medicines Agency (EMA). European Public Assessment Report Annex I Product Information. Arava. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000235/WC500026289.pdf [Last accessed 23 June 2013]
- European Medicines Agency (EMA). European Public Assessment Report. Annex I Product Information. Gilenya. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf [Last accessed 2 September 2012]
- Summary of Product Characteristic. Mycophenolate mofetil. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000082/WC500021864.pdf [Last accessed 2 September 2012]
- Summary of Product Characteristics. Valproate. Available from: http://db.cbg-meb.nl/mri/spc/nlh-0678-001-002.pdf [Last accessed 23 June 2013]
- Summary of Product Characteristics. Carbamazepine. Available from: http://db.cbg-meb.nl/IB-teksten/h24266.pdf [Last accessed 27 June 2013]
- Committee for medicinal products for human use. Guideline on risk assessment of medicinal product on human reproduction and lactation: from data to labelling. 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003307.pdf [Last accessed 12 February 2012]
- European Medicines Agency (EMA). European Public Assessment Report. Erivedge. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002602/WC500146820.pdf [Last accessed 2 May 2013]
- European Medicines Agency (EMA). Annex I of the Summary information on a referral opinion following an arbitration pursant to article 29 of directive 2001/83/EC for isotretinoin. 2003. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Isotretinoin_29/WC500010881.pdf [Last accessed 2 May 2013]
- Prieto L, Spooner A, Hidalgo-Simon A, et al. Evaluation of the effectiveness of risk minimization measures. Pharmacoepidemiol Drug Saf 2012;21:896-9
- Crijns I, Straus S, Luteijn M, et al. Implementation of the harmonized EU isotretinoin Pregnancy Prevention Programme: a questionnaire survey among European regulatory agencies. Drug Saf 2012;35:27-32
- Teichert M, Visser LE, Dufour M, et al. Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data. Drug Saf 2010;33:315-26
- Cheetham TC, Wagner RA, Chiu G, et al. A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study. J Am Acad Dermatol 2006;55:442-8
- Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program. Arch Dermatol 2005;141:563-9
- Shin J, Cheetham TC, Wong L, et al. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system. J Am Acad Dermatol 2011;65:1117-25
- Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995;333:101-6
- Schaapveld M, Visser O, Siesling S, et al. Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer 2010;46:160-9
- Rose ML, Strange G, King I, et al. Congenital heart disease-associated pulmonary arterial hypertension: preliminary results from a novel registry. Intern Med J 2012;42:874-9
- Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-44